<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences

Find me on:

Recent Posts

Drug Discovery Success Rates | Role of Preclinical Study Design.

Posted by MD Biosciences on Apr 22, 2015 12:16:55 AM

In 2014, an article was published in Nature analyzing the clinical development success rates for investigational drugs. It's no surprise that the success rates are still somewhat dismal with 1 in 10 drugs that enter clinical phases pushing through to FDA approval. The article breaks down the success rate in each phase for differing classes of drugs as well as various therapeutic indications. NMEs were found to have the lowest success rates in every phase of development (7.5%) whereas biologics had nearly two times the success rate (14.6%).

Read More

Topics: Preclinical Discovery

Translating Preclinical Data to the Clinic

Posted by MD Biosciences on Mar 24, 2015 1:07:37 PM

It's a question that comes up regularly, from scientists who contact us to publications to conference lectures. One of the challenges in preclinical drug discovery is how translatable is the preclinical data from animal studies to the human situation?

Read More

Topics: in vivo pain models, Preclinical Discovery

The Value of Phenotypic Screening

Posted by MD Biosciences on Mar 24, 2015 11:21:23 AM

Preclinical strategies used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. In the earlier days of drug de- velopment, phenotypic screening was largely employed and identified molecules that modify a disease phe- noytpe by acting on a previously unidentified target or simultaneously on more than one target. In the 1980s, advances in molecular biology and genomics led to a shift in developing compounds against defined targets that were implicated in disease. The success rate of clinical stage candidates, however has not improved and phenotypic screens are coming back into light. 

In a recent publication, analysis of different discovery strategies for 259 approved new molecular entities (NMEs) and new biologics between 1999 and 2008 showed that the contribution of phenotypic screening to the drug discovery of first-in-class small molecule drugs exceeded that of target-based approaches in an era when the major focus was on target-based approaches (Swiney, D and Anthony, J. Nature Rev. Drug Disc. (2011) 10:507-519). 


Phenotypic Screening gets another look?

While phenotypic screening is getting a second look and making its way back into some biopharma's discovery toolbox, many phenotypic screens are established on the basis of cellular systems or systems that are set to ‘mimic’ the in vivo environment. These systems range from a simple single cell types to more complex cell or tissue systems. What can occur with in vitro phenotypic screens that aim to mimic the in vivo environment is:

  • The screen is most often selectively look at single pathways and therefore miss inter-pathway interactions

  • The screens, while aiming to mimic the in vivo environment, don’t predict the in in vivo effect and unexpected biology, interactions or potential toxicity effects that are often observed in vivo.

  • Can miss pharmaceutical candidates whose pharmocology isn't evident until it is in a complex biological system.

This has led us to develop a more comprehensive, in vivo phenotypic screening platform, Senerga®. The Senerga® Phenotypic Screening platform consists of a series of matrices designed to cover maximum biological pathways to identify pharmaceutically relevant candidates that also show no predictive toxicity effects early on in the discovery process. This enables researchers to move beyond well-defined targets from the literature or their existing programs and discover new disease biology and potential targets.  

The benefit to using this powerful screening program:

  • Enables researchers to see effects on disease phenotypes in a complex biological setting with multiple pathways involved.
  • Obtain predictive toxicology data at the same time.
  • Expands therapeutic potential of libraries as it covers maximum biological pathways with biomarkers to support potential mechanisms
  • Identify hits relatively quickly that can be put through further target validation or efficacy proof of concept studies. 

With the need to move quickly and fill drug discovery pipelines with new candidates, this phenotypic screening platform is designed to efficiently screen compound libraries rapidly (within 3 - 9 months dependent on the size of the library). The resulting data is mined for hits that are identified from modified disease phenotypes and biological pathways. If you'd like to speak with a scientist about utilizing the Senerga® Phenotypic screening platform, please fill out the following details and a scientist will be in contact with you. 


Read More

Assessing Subjective Pain | Preclinical Pain Studies

Posted by MD Biosciences on Feb 19, 2015 10:57:04 AM

Rodent models of pain such as nerve injury models are important to understand the mechanisms that may contribute to human neuropathic pain. Imaging studies in human have identified cortical regions specifically involved in the subjective, conscious perception of pain. Although laboratory animals process painful stimuli using similar mechanisms and thresholds of awareness as humans, it is much harder to assess the subjective pain experienced by animals as they can not self-report. This has led researchers to rely on objective measures of pain-related behaviors such as evoked responses to noxious stimuli. Humans, however, are able to voice discomfort, which provides rapid and direct access to the subjective experience. 

Read More

Topics: in vivo pain models

Increase Validity of Preclinical Pain Research

Posted by MD Biosciences on Jan 20, 2015 11:12:09 AM

If you work in drug discovery and development, you are well aware of the failure rate at clinical trials. Industry estimates are that clinical candidates have a 85-90% chance of failure during clinical trials, the most costly stage of evaluation. A report in Nature Biotechnology 32, 40–51  breaks this success/failure rate down between phases as well as the likelihood of approval from the start of clinical trials. For candidates that are suspended during clinical stages, 83% of these reported efficacy or safety as the reason for suspension. 

This is costly and time consuming for drug developers. So is there a way to increase the predictability from preclinical phases to clinical phases?  We have been evaluating this question for a number of years in our Research Group at MD Biosciences. Animal models used in preclinical development phases are pivotal for understanding mechanisms that contribute to human disease conditions and effective therapies. Rodent models are commonly employed due to their reproducibility and simplicity, however the predictability to the clinic is often times lacking.

Read More

Topics: Pain, Neuro/CNS, in vivo pain models

Preclinical Pig Models for Therapeutic Studies

Posted by MD Biosciences on Nov 7, 2013 11:08:00 AM

Historically, rodent models have been used for the discovery of various biological mechanisms within disease states as well as preclinical development of therapeutics. Unfortunately there are many ways that the biology of rodents fails to accurately predict the clinical conditions of humans - this is particularly the case in pain therapeutics. This can be evidenced by the estimates that as many as 80% of all drug candidates across therapeutic areas fail in the most expensive stages of development - clinical trials. While the failures can be attributed to various reasons such as insufficient efficacy, unacceptable safety profiles or PK properties. With the high cost of developing new therapeutics, there is certainly the need to validate biological and pharmacological findings in models using larger species, which can also address some of the known differences between rodents and human. The pig is one species which may provide more translatable data to the human condition, particularly in therapeutic areas such as cardiovascular, skin or wound healing conditions, metabolic and pain.

Read More

Topics: Dermal, Pain, CRO/outsourcing, Cardiovascular, metabolic

Preclinical Models for Diabetic Neuropathy

Posted by MD Biosciences on Sep 5, 2013 9:12:00 AM

Diabetic neuropathies include a range of dysfunctions of the peripheral nerves that can be broadly categorized into generalized symmetric polyneuropathies and focal/multifocal neuropathies. Diabetic neuropathy (DN) is the most common long-term complication suffered by individuals afflicted with either type 1 diabetes (T1D) or type 2 diabetes (T2D). It is the leading cause of non-traumatic amputations and results in significant morbidity, mortality, and economic burden. Of patients suffering from DN, approximately 30% experience pain that is severe, debilitating, largely unresponsive to current pharmacotherapies, and persistent for several years. DN pain is often localized to the feet, described as “burning” or “sharp,” and worsens at night or during periods of fatigue or stress. DN pain can be spontaneous and/or can be in the form of either allodynia (pain caused by a normally benign stimulus) or hyperalgesia (exaggerated pain caused by a normally mildly painful stimulus) or both. [1-3] 

Read More

Topics: metabolic

Cell Types Involved in ischemic Neuroinflammation

Posted by MD Biosciences on Sep 4, 2013 11:10:00 AM

Post-stroke neuroinflammation is a very complex phenomenon involving multiple resident and invading cell types at varying degrees of differentiation or activation each expressing specific subsets of diffusible factors, receptors, cellular adhesion molecules, and other markers, all of which is changing as time passes to create an initially neurotoxic and then finally neuroprotective environment. This inflammatory process in the penumbra offers a broad array of potential cellular and molecular targets with much wider therapeutic windows. At the cellular level, neurons, microglia, astrocytes, and cerebrovascular endothelial cells are the first affected by the ischemic conditions and their responses to massive cell death in neighboring tissue initiates the precisely timed arrival of successive subsets of leukocytes – first neutrophils, followed by monocytes and macrophages, and finally T cells. Targeting these cells via manipulation of their phenotypes or activation states or their movements into lesion sites or their release of harmful mediators represents a major investigative pathway toward potential therapeutics for ischemic stroke sufferers. [1-4]

Read More

Topics: Neuro/CNS

Cognitive Impairment Neurodegenerative Disease Models

Posted by MD Biosciences on Jul 31, 2013 7:36:00 AM

Diseases of the central nervous system are extremely debilitating, increasingly common, and affect millions of people worldwide. Neurodegenerative diseases often result in a combination of cognitive and motor deficits that affect an individual’s ability to perform daily tasks. Affected patients become dependent on medical services and family support as their disease progresses. Improvements in health have lengthened lifespan; however, this has resulted in a higher incidence of neurodegenerative conditions that affect the aging population. Genetics often has a major role in the development of neurodegenerative diseases and disease severity sometimes increases with each generation. However, environmental factors may be equally important in contributing to the severity, progression, and outcome of patients with other types of neurodegenerative disorders. Exposure to environmental toxins, metals, industrial chemicals, and certain dietary or lifestyle factors, may result in damage to the nervous system. Acute brain injuries, such as head trauma or oxygen deprivation, can also result in cognitive impairments.

Although there are a variety of pathways leading to neurodegenerative disease, the end result is the same: loss of function in the central nervous system and resulting impairments. Many neurodegenerative disorders are progressive in nature, resulting in a decline in function that may occur over several years or several decades. While there are some treatments available for neurodegenerative disorders, there are no cures. Therefore, there is great interest in researching neurodegenerative diseases and a need to halt or slow the process of cognitive decline. Understanding the basic biological mechanism of disease and cognitive impairment is pertinent for the development of therapeutics. 

The outcome in oxygen stress and neurodegenerative diseases

Homeostasis is critical for cell viability and cell maintenance. In cases of oxygen deprivation, autoimmune disease, or expression of disease factors, the cell is no longer able to maintain homeostasis and perform its necessary functions. Affected cells may die by necrosis or by apoptosis. When dead cells accumulate, reactive glial cells migrate to the site of injury and begin clearing the debris, but they also form scars that hinder axon regeneration and remylination [1]. Immune activation of glia may cause bystander effect and result in damage to the surrounding tissues. While it was once thought that cells of the central nervous system were unable to regenerate, we now know that restrictive microenvironmental factors are mostly responsible for preventing repair [2]. Strategies such as stem cell therapy, nanoparticle drug delivery, and gene therapy are being studied to determine if modulating the cellular microenvironment can lead to repair in the central nervous system [3-5].

Patients with cell death as a result of prolonged oxygen deprivation or disease have functional deficits. Although the young brain does display a high degree of plasticity, the adult brain is not easily able to regain lost function. After a stroke, the adult brain must undergo extensive changes in the motor cortical network in order to overcome resulting motor deficits. In patients with autoimmune disorders or neurodegeneration, the disease is typically progressive and patients are less likely to show any improvement in cognitive or motor function. Both cognitive function and motor function are typically affected by these progressive and acute brain injuries. Distinguishing between loss of motor function and loss of cognitive function is important for accurately studying these diseases and injuries in animal models. 

Distinguishing between motor function and cognition

Differentiating between motor function and cognitive deficits can sometimes be a difficult task. For example, slow and slurred speech may lead a listener to suspect a patient has problems with language processing. However, difficulty with speech could be caused by damage to the hypoglossal nerve that controls movement of the tongue. Different areas of the central nervous system are responsible for voluntary (cognitive) and involuntary (reflexive) muscle movements. Deficits in purely motor function are often seen as problems in coordination, balance, and strength. A majority of involuntary motor function is controlled by the spinal cord. Even processes like walking are regulated by a feedback loop within the spinal cord and individuals do not consciously consider how to lift and place each leg. The cerebellum coordinates movement fluidity through feedback prediction. Patients with degeneration of the cells of the cerebellum have difficulty reaching for an intended target. Other motor deficits may lead patients to experience tremors, which are common in Parkinson’s disease. While lost motor functions are extremely problematic in performing daily tasks, some functions may be regained under certain conditions. In one study, 76% of patients regained motor functions six months after suffering a stroke [6]. Motor function was also regained in monkey models of brain lesions [7].

Cognitive regulation of motor function (motor planning) is controlled by the cerebral cortex. When an individual makes a decision to move, the cerebral cortex sends signals to the spinal cord where information is streamlined and relayed to muscles. Defects in cognitive planning may hijack successful completion of the motor task at hand. One of the paradoxes of Parkinson’s disease is that patients lose the cognitive decision to move, however the motor function needed to perform the action is maintained. Cognitive impairments do not appear to resolve as easily as motor impairments. The probability of long-term cognitive improvement after a stroke was only 54% for patients with damage to the left hemisphere of the brain [8]. When oxygen deprivation or neurodegenerative processes occur, patients often experience varying de- grees of loss of motor function combined with cognitive deficits. A stroke patient usually has muscle weakness on the contralateral side of the body and cognitive impairments related to the area of the brain that was damaged.

Because disease patients often experience varying degrees of motor and cognitive impairments, it is difficult to study neurodegenerative disease and cognition in humans. Similar biological processes control loss of cognitive function in humans and animals; therefore mouse models recapitulate the cell biology resulting in cognitive decline.

Mouse models provide many advantages to the study of neurodegenerative disorders. Models such as EAE for neuroimmunological disorders, the 4VO and MCAo for oxygen deprivation and 6-OHDA for neurodegenerative disease can be used to study cognitive impairments related to human disease.


Download the rest of the article to continue reading about measuring cognitive impairment in preclinical models. 



  1. Fawcett J.W., & Asher, R.A. The glial scar and central nervous system repair. Brain Research Bulletin. 49, 377-391 (1999)

  2. Horner, P.J., Gage, F.H. Regenerating the damaged central nervous system. Nature 407, 963-970 (2000)

  3. Berry, M., Barrett, L., Seymour, L., Baird, A., Logan, A. Gene therapy for central nervous system repair. Current Opinion in Molecular Therapies 3, 338-349 (2001)

  4. Aboody, K., Capela, A., Niazi, N., Stern, J.H., Temple, S. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone. Neuron 70, 597-613 (2011)

  5. Chen, B., Bohnert, D., Borgens, R.B., Cho, Y. Pushing the science forward: chitosan nanoparticles and functional repair of CNS tissue after spinal cord injury. Journal of Biological Engineering 7, 15 (2013) [Epub ahead of print]

  6. Bonita, R., Beaglehole, R. Recovery of motor func- tion after stroke. Stroke 19, 1497-500 (1988)

  7. Black, P., Markowitz, R.S., Cianci, S.N. Recovery of motor function after lesions in motor cortex of monkey. Ciba Foundation symposium 34, 65-83 (1975) 


Read More

Topics: Neuro/CNS

IMQ-induced Psoriasis Model | Correlates with Human Psoriasis

Posted by MD Biosciences on Apr 29, 2013 4:28:00 PM

First let's start by talking about what makes a good preclinical model of psoriasis?

A good pre-clinical psoriasis model should obviously re-capitulate the key features of the clinical disease in humans. Therefore, a plausible model will exhibit the following criteria:

Read More

Topics: Dermal, Psoriasis